$327.64
0.10% day before yesterday
NYSE, Jan 02, 10:11 pm CET
ISIN
US0311621009
Symbol
AMGN

Amgen Stock price

$327.64
-10.72 3.17% 1M
+30.79 10.37% 6M
+0.33 0.10% YTD
+68.36 26.37% 1Y
+65.00 24.75% 3Y
+100.98 44.55% 5Y
+169.30 106.92% 10Y
+248.78 315.47% 20Y
NYSE, Closing price Fri, Jan 02 2026
+0.33 0.10%
ISIN
US0311621009
Symbol
AMGN
Industry

New AI Insights on Amgen Insights AI Insights on Amgen

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$176.4b
Enterprise Value
$221.6b
Net debt
$45.1b
Cash
$9.4b
Shares outstanding
538.0m
Valuation (TTM | estimate)
P/E
25.3 | 15.1
P/S
4.9 | 4.8
EV/Sales
6.2 | 6.0
EV/FCF
16.9
P/B
18.3
Dividends
DPS
$9.52
Yield 1Y | 5Y
2.9% | 3.2%
Growth 1Y | 5Y
5.8% | 8.3%
Payout 1Y | 3Y
119.1% | 78.6%
Increased
15 Years
Financials (TTM | estimate)
Revenue
$36.0b | $37.1b
EBITDA
- | $21.6b
EBIT
$12.1b | $16.2b
Net Income
$7.0b | $11.7b
Free Cash Flow
$13.1b
Growth (TTM | estimate)
Revenue
10.6% | 10.9%
EBITDA
- | 41.4%
EBIT
93.7% | 68.0%
Net Income
65.6% | 185.4%
Free Cash Flow
108.9%
Margin (TTM | estimate)
Gross
72.1%
EBITDA
- | 58.2%
EBIT
33.6%
Net
19.5% | 31.5%
Free Cash Flow
36.5%
Financial Health
Equity Ratio
6.4%
Return on Equity
69.6%
ROCE
17.7%
ROIC
-
Debt/Equity
5.7
More
EPS
$12.9
FCF per Share
$24.4
Short interest
2.6%
Employees
28k
Rev per Employee
$1.2m
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

41 Analysts have issued a Amgen forecast:

22x Buy
54%
16x Hold
39%
3x Sell
7%

Analyst Opinions

41 Analysts have issued a Amgen forecast:

Buy
54%
Hold
39%
Sell
7%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
35,971 35,971
11% 11%
100%
- Direct Costs 10,051 10,051
22% 22%
28%
25,920 25,920
32% 32%
72%
- Selling and Administrative Expenses 6,956 6,956
7% 7%
19%
- Research and Development Expense 6,844 6,844
19% 19%
19%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 12,075 12,075
94% 94%
34%
Net Profit 7,005 7,005
66% 66%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Positive
Invezz
3 days ago
The “Dogs of the Dow” strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow's performance, Simpson is zeroing in on three names he sees as essential for income-focused investors: Amgen, Verizon, and Home Depot.
Neutral
Seeking Alpha
7 days ago
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...
Positive
Seeking Alpha
8 days ago
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a cholesterol-lowering medication, were $794 million in Q3, up 40% YoY.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 28,000
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today